🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9112 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:16 UTC
9112
Studies in scope
industry-sponsored, all four open statuses
4950
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5295 Florida 4397 Illinois 2479 Georgia 2346 Arizona 2231
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company190 Merck Sharp & Dohme LLC183 AbbVie172
State
California5295 Florida4397 Illinois2479 Georgia2346 Arizona2231
All 51 states
Target enrolment
to
9112 of 9112 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
Response to an Investigational Device in Patients With Restless Legs Syndrome
NCT06866132Restless Legs Syndrome
Noctrix Health, Inc.
Not applicable
20
California
2025-03-11
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Active, closed
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Arthrosi Therapeutics
Phase 3
750
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2025-03-11
Recruiting
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NCT06769659Epilepsy, Generalized, Epilepsy, Absence
NeuroPro Therapeutics, Inc.
Phase 2
12
Arkansas
2025-03-11
Recruiting
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
NCT06940739Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Iovance Biotherapeutics, Inc.
Phase 1/2
42
Colorado, North Carolina, Tennessee
2025-03-11
Active, closed
A Study of SPY003-207 in Healthy Volunteers
NCT06873724Healthy
Spyre Therapeutics, Inc.
Phase 1
59
California
2025-03-10
Recruiting
Non-invasive Central Venous Pressure Estimation in Pediatric Patients
NCT06885073Central Venous Pressure
Compremium AG
Not applicable
100
District of Columbia
2025-03-10
Recruiting
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
NCT06789445Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
BlueRock Therapeutics
Phase 1/2
54
California, Florida, Pennsylvania, Texas, Wisconsin
2025-03-10
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Active, closed
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Recruiting
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06578624Solid Tumor
Lamassu Bio Inc
Phase 1/2
70
Ohio
2025-03-10
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Umoja Biopharma
Phase 1
106
California, Illinois, Missouri, Nebraska, Ohio, Washington
2025-03-10
Active, closed
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802Encephalitis
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Recruiting
Parent-Child EF Intervention
NCT06924307Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children
Koronis Biomedical Technologies
Not applicable
140
Minnesota, New York
2025-03-10
Recruiting
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT06514001Alzheimer Disease
Amydis Inc.
Phase 2
25
Arizona
2025-03-07
Recruiting
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085Hypogonadism, Male
Halozyme Therapeutics
Phase 3
100
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-03-07
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
New York
2025-03-06
Active, closed
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
GlaxoSmithKline
Phase 1/2
83
California, Iowa, New Jersey, Ohio, Rhode Island, Wisconsin
2025-03-06
Recruiting
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
NCT06924320Obesity and Obesity-related Medical Conditions
Pfizer
Phase 1/2
381
California
2025-03-06
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
AbbVie
Phase 1/2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Massachusetts
2025-03-06
Active, closed
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
NCT06397131Macular Telangiectasia Type 2
Neurotech Pharmaceuticals
Phase 3
12
California, Michigan, Texas
2025-03-06
Active, closed
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026Psoriatic Arthritis, Overweight or Obesity
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
By invitation
Karma Ambispective Study
NCT07207187Subjects Treated With Karma Fixation System as Part of Their Spine Surgery
Spinal Elements
Observational
100
Arizona, Florida, Louisiana, Oklahoma
2025-03-06
Recruiting
APOL1 Genotyping CTA Clinical Performance Study
NCT06839833APOL1-mediated Kidney Disease
Almac Diagnostic Services LLC
Not applicable
2,000
North Carolina
2025-03-06
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Active, closed
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987APOL1-Mediated Kidney Disease
AstraZeneca
Phase 2
57
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-05
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-05
Recruiting
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
NCT06714253Radiation-Induced Xerostomia and Hyposalivation
RiboX Therapeutics Ltd.
Phase 1/2
42
Iowa, Maryland, New York, Pennsylvania
2025-03-05
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268Obesity
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche
Phase 2
130
Alaska, California, Colorado, Florida, Idaho, Illinois, Iowa, Kentucky
2025-03-05
Active, closed
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597Prader-Willi Syndrome, Obesity, Hyperphagia
Rhythm Pharmaceuticals, Inc.
Phase 2
18
Florida
2025-03-04
Active, closed
Observational Study to Evaluate the STALIF® C FLX, STALIF® M FLX, STALIF® L FLX Cages and FORTOS-C®
NCT06876311Degenerative Cervical Disc Disease, Degenerative Lumbar Diseases
Silony Medical GmbH
Observational
100
California
2025-03-04
Recruiting
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
NCT06890923Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD
Phase 2
55
Massachusetts
2025-03-04
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
GlaxoSmithKline
Phase 1/2
305
California, Colorado, New York, North Carolina, Ohio
2025-03-04
Recruiting
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
NCT06952426Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Observational
300
Massachusetts
2025-03-04
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
Takeda
Phase 3
1,088
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-03
Active, closed
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621Alzheimer's Disease (AD)
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Recruiting
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
NCT06613217Relapsed Adult AML
Pacylex Pharmaceuticals
Phase 1
35
Texas
2025-03-03
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Active, closed
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Alnylam Pharmaceuticals
Phase 1/2
105
California, District of Columbia, Florida, New Jersey, North Carolina, Texas
2025-03-03
Recruiting
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044Major Depressive Disorder (MDD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, Arkansas, California, Colorado, Florida, Illinois, Missouri, Nevada
2025-03-03
Active, closed
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics
Phase 3
480
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-03-03
Recruiting
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06560762Heart Failure With Preserved Ejection Fraction (HFpEF)
Secretome Therapeutics
Phase 1
12
Illinois, Texas
2025-03-03
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Active, closed
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231Multiple System Atrophy
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055Non-small Cell Lung Cancer
BioNTech SE
Phase 2
60
Alabama, Florida, Kentucky, New York, Texas
2025-03-03
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Recruiting
2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles
NCT07222397Photodamaged Skin, Rhytids, Lines Skin, Wrinkles and Rhytides
FA Corporation
Not applicable
20
Texas
2025-03-01
Not yet open
Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study
NCT06264505Soft Tissue Sarcoma
Power Life Sciences Inc.
Observational
500
California
2025-03
Not yet open
Understanding of Participation Trends Within Generalized Anxiety Disorder Patients Involved in Clinical Trials
NCT06254157Generalized Anxiety Disorder
Power Life Sciences Inc.
Observational
500
California
2025-03
Not yet open
An Observational Exploration of Clinical Trials Targeting Traumatic Brain Injury
NCT06264518Traumatic Brain Injury
Power Life Sciences Inc.
Observational
500
California
2025-03
Not yet open
Understanding Patient Engagement Trends in TBI Clinical Research
NCT06288698TBI
Power Life Sciences Inc.
Observational
500
California
2025-03
Not yet open
Assessing Patient Engagement in Keratoconus Clinical Research
NCT06288737Keratoconus
Power Life Sciences Inc.
Observational
500
California
2025-03
Not yet open
Delving Into Participation Trends of Scleroderma Clinical Trials
NCT06264492Scleroderma
Power Life Sciences Inc.
Observational
500
California
2025-03
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
Clasp Therapeutics, Inc.
Phase 1
90
Arizona, California, Florida, Illinois, Kentucky, Maryland, New Jersey, New York
2025-02-28
Active, closed
A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.
NCT06922955Nasal Airway Obstruction
Aerin Medical
Observational
400
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan
2025-02-28
Active, closed
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
NCT06856577Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Adverum Biotechnologies, Inc.
Phase 3
311
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-02-28
Active, closed
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
NCT06812988Type 1 Diabetes Mellitus
Sanofi
Phase 2
84
Georgia, Michigan, Texas, Utah
2025-02-28
Recruiting
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
NCT06764316Hepatocellular Carcinoma
Bayer
Phase 1
148
Alabama, California
2025-02-28
Active, closed
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
NCT06838000Pneumococcal Infections
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
California, Florida, Georgia, Iowa, Kentucky, Mississippi, Nebraska, New York
2025-02-28
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
Incyte Corporation
Phase 3
600
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-02-28
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Recruiting
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
522
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline
Phase 2
68
Michigan, New York, Tennessee, Texas, Washington
2025-02-28
Recruiting
Glycemic Metrics and Patterns in People With and Without Prediabetes
NCT06921902Pre Diabetes
Abbott Diabetes Care
Observational
2,000
Oregon
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Maryland, Missouri, North Carolina, Pennsylvania, Virginia
2025-02-28
Active, closed
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181Pneumococcal Immunization
Sanofi
Phase 3
580
California, Florida, Iowa, Kentucky, Louisiana, New York, Pennsylvania, South Carolina
2025-02-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
NCT06808477Atopic Dermatitis
Bambusa Therapeutics
Phase 1
237
California, New York
2025-02-27
Recruiting
CLAiR Pivotal Study
NCT06808334No Condition
Toku Eyes Ltd
Observational
942
Ohio
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Recruiting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394Breast Neoplasms, Breast Cancer
Merck Sharp & Dohme LLC
Phase 1/2
81
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865Osteoarthritis (OA) of the Knee
Pacira Pharmaceuticals, Inc
Phase 2
135
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-02-26
Active, closed
A Study of Oral E1018 in Healthy Adult Participants
NCT06854042Malaria, Healthy Participants
Eisai Inc.
Phase 1
32
Texas
2025-02-26
Recruiting
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
NCT07558668Moderate to Severe Atopic Dermatitis
Sitryx Therapeutics Ltd
Phase 1
149
Arkansas, California, Indiana, Ohio, Pennsylvania, Utah
2025-02-26
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Recruiting
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
NCT06866483Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
ZS Associates
Observational
1,000
Illinois
2025-02-26
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379Solid Tumors
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
Recruiting
A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction
NCT06864884Acute Post Operative Pain, Third Molar Extraction Surgery
Arcato Laboratories, Inc.
Phase EARLY_PHASE1
30
Utah
2025-02-26
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 2
200
Minnesota, North Carolina, Pennsylvania
2025-02-25
Recruiting
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
NCT06938867E Coli Infections, Allogenic Transplant Patients
SNIPR Biome Aps.
Phase 1/2
24
California, Maryland, Minnesota, New York, Pennsylvania, Texas, Washington
2025-02-25
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
NCT06804824Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1
220
Michigan, Texas, Utah, Virginia
2025-02-25
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Recruiting
Identifying Patterns in the Breath of Individuals With Breast Cancer
NCT06512350Breast Cancer
Breathe BioMedical Inc
Observational
5,175
District of Columbia, Florida, North Carolina, Pennsylvania
2025-02-25
Recruiting
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
NCT06837246Cognition, Concentration, Attention, Focus
Pharmavite LLC
Not applicable
422
Illinois
2025-02-24
Rows per page Showing 3801–3900 of 9112
Previous 37 38 39 40 41 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-usa?page=39

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
→

Browse trials by condition

Advanced Solid Tumor (143) Breast Cancer (139) Obesity (123) Multiple Myeloma (109) Advanced Solid Tumors (89) Colorectal Cancer (83) Solid Tumor (81) Overweight (77) Ovarian Cancer (74) Healthy (73) Prostate Cancer (73) Heart Failure (72) Non-Small Cell Lung Cancer (70) Cancer (65) Melanoma (63)
→

Browse trials by state

California (5295) Florida (4397) Illinois (2479) Georgia (2346) Arizona (2231) New York (2126) Colorado (2066) Texas (1969) Massachusetts (1836) Michigan (1481) Alabama (1288) Connecticut (1274) Maryland (1267) Ohio (1252) Indiana (1114)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.